Mechanism of Action
Dupilumab is a human monoclonal IgG4 antibody that acts as an interleukin-4 (IL-4) receptor subunit alpha (IL-4Rα) antagonist.[1–3] This receptor is found on both IL-4 and interleukin-13 (IL-13). Binding at the IL-4Rα site inhibits IL-4 and IL-13 signaling through type II receptors. A number of cells involved in inflammatory response express IL4R, including mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, and goblet cells. Administration of dupilumab results in inhibition of proinflammatory cytokine release, as well as the production or release of chemokines, nitric oxide, and IgE.
Pediatr Pharm. 2019;25(6) © 2019 University of Virginia